)
Visual
test
TFF Pharmaceuticals
TFF Pharmaceuticals (TFFP) investor relations material
TFF Pharmaceuticals has been delisted
TFF Pharmaceuticals Q2 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2024 earnings summary14 Aug, 2024
Executive summary
TFF Pharmaceuticals focuses on inhaled dry powder drugs using Thin Film Freezing (TFF) technology, with TFF TAC and TFF VORI as main candidates in Phase 2 trials as of June 2024.
Positive Phase 2 TFF TAC data show strong safety, efficacy, and biomarker improvements for lung transplant rejection prevention, with 13 patients enrolled and all completing 12 weeks opting for long-term extension.
No mortality or severe adverse events in TFF TAC trial; kidney function maintained and one minimal acute rejection case resolved.
The company prioritized TFF TAC development in March 2024 and is evaluating strategic options for TFF VORI.
Strategic initiatives include partnership evaluations, government-funded MCM development, and advancing universal influenza vaccines to preclinical testing.
Financial highlights
Revenue for Q2 2024 was $650,222, up 95% from $333,351 in Q2 2023, mainly from grants and feasibility agreements.
Net loss for Q2 2024 was $4.5 million, improved from $5.0 million in Q2 2023; net loss for the six months ended June 30, 2024 was $10.2 million, down from $12.1 million in the prior year period.
Operating expenses for Q2 2024 decreased 14% year-over-year to $4.6 million, with R&D at $2.6 million (down 3%) and G&A at $2.0 million (down 24%).
Cash and cash equivalents as of June 30, 2024 were $4.4 million, with working capital of $2.3 million.
Accumulated deficit reached $128.5 million as of June 30, 2024.
Outlook and guidance
Management expresses substantial doubt about the company’s ability to continue as a going concern over the next 12 months without additional capital.
The company plans to seek further funding through equity, debt, licensing, or partnerships and may adjust its business plan to conserve capital.
Enrollment in the TFF TAC Phase 2 study is expected to end in the second half of 2024; TFF VORI Phase 2 trials have concluded.
Next TFF TAC study design is being finalized with regulatory update expected later in the fall.
Detail TFF TAC funding strategy
How to mitigate TFF TAC low-dose rejection risk?
Update on non-TFF TAC pipeline progress
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income. - 6 FebFFIE
Raising capital for global EV and AI expansion, with regulatory and dilution risks highlighted.
TFF Pharmaceuticals
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
TFF Pharmaceuticals Inc develops and commercializes innovative inhalable therapeutics using its proprietary Thin Film Freezing technology. Its focus areas include respiratory diseases, infectious diseases, and immunology. The company is headquartered in Austin, Texas, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage